Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,708 total articles
Delek Logistics Partners (DKL) presents an actionable long trade: buy near $53.96, target $61.00, stop $48.50. The combination of an 8%-plus yield, record adjusted EBITDA in 2025, a larger third-party revenue mix, and bullish momentum argue for a re-rating. Key risks include commodity exposure, distribution sustainability, and macro-driven midstrea…
Blue Owl (OWL) is a beaten-down alternative asset manager trading near $10 with a ~9% yield, meaningful free cash flow and technical signs of accumulation. This trade idea outlines a high-conviction long with entry, stop and target, a fundamental case tied to fee stability and asset-liability optionality, catalysts that could re-rate the stock, and…
BWX Technologies (BWXT) is trading below its April highs after a strategic commercial acquisition and a sector pullback. The business is cash-generative, backed by long-dated government work, and benefits from renewed political and commercial support for nuclear power. For traders willing to accept a crowded valuation, a disciplined long into earni…
JD.com trades at a $41.2B market cap with a P/E of 16.9 and a 3.23% yield. Its logistics arm is increasingly monetizable through automation and external customers, while AI and new-business initiatives create earnings optionality. Technicals sit near support and institutional short interest is manageable — a tactical long here targets a re-rating t…
Bristol-Myers Squibb (BMY) is trading near $58.50 with a sizable growth portfolio led by CAR-T and recently stronger-than-expected Q1 results. The market is underappreciating durable revenue growth from Breyanzi and allied biologics, plus a healthy free cash flow stream that supports dividends and reinvestment. We lay out a long trade with a clear …
Upstart's shares are trading near $32.77 with a $3.1B market cap despite improving loan trends and a manageable short interest profile. We see a favorable risk/reward for a mid-term swing: entry $32.75, stop $30.50, target $43.00 (mid term - 45 trading days). The trade assumes an earnings beat and stabilization of Model 22 approval dynamics; litiga…
Hovnanian Enterprises (HOV) is a national homebuilder trading at a conservative valuation, with improving operating results, strong free cash flow, and tangible catalysts — from lot growth to international partnerships — that support a meaningful upside. This trade idea lays out an actionable entry at $110.47, a $150 target and a $95 stop, with a p…
Equinor (EQNR) is a cash-generative integrated energy company with record production, strong 2025 results and active buybacks. I want to buy shares at $35 with a stop at $31.50 and will take profits at $45. The trade is a long directional play over the next 180 trading days, aiming to capture renewed commodity strength, buyback support and improvin…
Vaxcyte's 31-valent conjugate vaccine (VAX-31) just cleared significant scientific and funding milestones. With positive Phase 1/2 data published in The Lancet and a $632.5M offering closed to fund late-stage programs and a planned $1B manufacturing buildout, the stock presents a tradeable long with asymmetric upside into late-2026/2027 regulatory …
Mitsui & Co. (MITSY) looks actionable after management laid out a new three-year plan and heavy interest from Berkshire Hathaway's team put trading houses back on investors' radars. At roughly $105.8B market cap, a 10% annual growth pathway and modest valuation (P/E ~18.8, P/B ~2.0) justify upgrading to a buy for a long-term (180 trading days) trad…
OpenText (OTEX) trades like a mature enterprise-software value play at roughly $5.8B market cap. With P/E ~13.3, EV/EBITDA ~6.9 and free cash flow near $878M, the stock looks priced for sideways growth. Recent operational signs, a public-sector distribution win and a planned divestiture of Vertica give catalysts for upside and a plausible path to a…
Prediction markets have received a lot of attention lately, but DraftKings' core licensed sportsbook and casino business remains the dominant, higher-margin route to monetizing sports fandom. With a market cap near $10.7B, positive free cash flow, and regulatory developments that favor licensed operators, DraftKings looks like a reasonable mid-term…
Gentex (GNTX) is a market leader in automotive vision and dimmable-glass technologies trading at roughly $4.9B market cap, with P/E ~13, EV/EBITDA ~8.4, and free cash flow north of $450M. The balance sheet is clean (debt-to-equity 0) and the company pays a steady $0.12 quarterly dividend. We like a tactically sized long position into $29 while prot…
Stoke Therapeutics is trading like a late-stage biotech with a blockbuster opportunity priced in. Zorevunersen's (reported in company materials as STK-001) potential to be disease-modifying in Dravet syndrome is the core bullish driver. The trade is long with an entry at $33.08, a $45.00 target and a $26.40 stop — horizon: long term (180 trading da…
Northeast Bank (NBN) is trading at a reasonable valuation against improving profitability and conservative leverage. With ROA/ROE above peers, solid free cash flow, and an upcoming dividend ex-date, the risk/reward favors a mid-term long. Enter at $125.00, stop at $118.00, target $140.00 over a 45 trading day horizon.
Tenet reported a mixed Q1 but raised full-year adjusted EPS guidance; fundamentals and cash flow support a constructive long trade from current levels. Entry at $183.29, target $235.00, stop $165.00 - long term (180 trading days).
Alnylam (ALNY) is digesting a strong multi-year story into a quieter calendar year. Valuation is rich, but revenue guidance and cash generation combined with a large TTR franchise and ongoing collaborations create a favorable risk-reward for a disciplined pullback buy. We lay out a mid-term trade plan with clear entry, stop, and target levels and a…
Ciena is converting a multi-billion-dollar backlog into revenue and free cash flow as hyperscalers build AI-optimized data centers. The stock is extended, but the fundamentals - fiscal Q1 revenue growth, a raised guide and a large orderbook - justify a long with a disciplined stop. Entry $537.34, target $700, stop $480; horizon: long term (180 trad…
SoFi has built scale in lending, deposits and investing that the market is under-pricing. With revenue growth running high, a healthy balance sheet and membership momentum, the Q1 selloff is an entry — not a verdict. This trade plan targets a recovery toward the mid-$20s over the next 180 trading days, with a protective stop below the recent low.
SoFi (SOFI) has retraced heavily since its November peak, but beneath the headline weakness is durable revenue growth, accelerating customer additions and a valuation that still looks reasonable given the growth profile. This trade idea targets a disciplined mid-term long: buy the dip near $16.00, cap risk with a $14.50 stop and aim for $20.00 as s…
Western Digital reported a Q3 beat on 04/30/2026, yet shares fell. The move looks driven by concerns around an NBM-related issue tied to SanDisk dynamics and NAND supply mix, combined with an already rich valuation and parabolic price action. We lay out a mid-term (45 trading days) short: entry $425.34, target $340.00, stop $460.00. This is a high-…
POET Technologies plunged after Marvell canceled orders and law firms opened class actions. The selloff looks overdone relative to the company’s addressable market in AI optics and the company’s IP platform. I outline a mid-term (45 trading days) trade: enter $6.90, stop $5.50, target $12.00, with clear catalysts and a strict risk framework.
Microsoft’s dip after an earnings-driven rotation into AI capex concerns created a tactical buying opportunity. With a $3.06T market cap, P/E ~24, $77.4B in free cash flow and Azure growth still in the high double-digits, the balance of data suggests upside. This trade idea lays out a mid-term (45 trading days) plan with entry, stop and target, plu…
Eli Lilly's Q1 2026 beat and guidance raise, driven by demand for Mounjaro and Zepbound plus a new oral GLP-1 approval, create a clear short-to-mid-term trading opportunity. Technicals confirm a fresh bullish leg and heavy volume today supports an immediate entry. Valuation is premium, but fundamentals and catalysts justify a measured buy with a de…
Plug Power has the headline ingredients for a turnaround: strong year-to-date performance, visible cost-cutting efforts, and market tailwinds in green hydrogen and AI data center demand. The stock trades at roughly $4.4B market cap with negative free cash flow but improving technical momentum. This trade idea is a disciplined long that banks on con…
